Hypothesis

α‑Ketoglutarate (AKG) supplementation restores age‑dependent decline in neuronal TET2 activity by increasing mitochondrial acetyl‑CoA production, which fuels the TET catalytic cycle and promotes locus‑specific DNA demethylation of synaptic plasticity genes. This epigenetic rejuvenation underlies the observed improvements in memory and the stronger lifespan extension seen in females, who exhibit higher expression of the AKG transporter SLC1A5 under estrogenic regulation.

Mechanistic Rationale

• AKG is a obligate cofactor for TET enzymes that convert 5‑methylcytosine to 5‑hydroxymethylcytosine, initiating DNA demethylation.[4]
• Mitochondrial TCA cycle flux generates acetyl‑CoA, which can be used for protein acetylation that enhances TET enzyme stability and nuclear import.[5]
• Aging reduces cytosolic AKG levels up to ten‑fold, limiting TET activity.[6]
• Estrogen upregulates SLC1A5, the primary AKG transporter, in neuronal cells, providing a sex‑biased increase in intracellular AKG.[2]
• Therefore, AKG supplementation should preferentially boost neuronal TET2 activity in females, leading to demethylation of promoters such as Bdnf and Syn1, enhancing synaptic plasticity and memory.[3]

Predictions and Experimental Design

1. Biochemical – Treat aged male and female mice with Ca‑AKG (2 g/kg diet) for 3 months; measure mitochondrial acetyl‑CoA, nuclear TET2 activity, and 5hmC levels in hippocampus. Expect a larger increase in females.[1,2]
2. Epigenetic – Perform locus‑specific bisulfite‑oxidation sequencing (oxBS‑seq) on Bdnf and Syn1 promoters; predict greater demethylation in AKG‑treated females correlating with rescued LTP and memory performance.[3]
3. Genetic – Use neuron‑specific Tet2 knockout mice; AKG should fail to improve memory or lifespan in both sexes, confirming causality.
4. Pharmacological – Co‑administer an ACLY inhibitor to block acetyl‑CoA synthesis; predict attenuation of AKG‑induced TET2 activation and epigenetic changes.
5. Human translational – In a pilot RCT, administer Ca‑AKG to post‑menopausal women and age‑matched men; assess plasma AKG, SLC1A5 expression in PBMCs, and blood‑based 5hmC at neuroplasticity loci over 6 months.

Potential Confounds and Falsifiability

If AKG extends lifespan without altering neuronal TET2 activity or 5hmC at plasticity genes, the hypothesis is falsified. Likewise, if SLC1A5 knock‑down abolishes the sex‑specific benefit but does not affect overall AKG levels, the mechanism would need revision.